AbbVie Inc.
ABBV · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $314,351 | $273,987 | $286,211 | $239,658 |
| - Cash | $5,524 | $12,814 | $9,201 | $9,746 |
| + Debt | $67,841 | $60,120 | $64,191 | $77,575 |
| Enterprise Value | $376,668 | $321,293 | $341,201 | $307,487 |
| Revenue | $56,334 | $54,318 | $58,054 | $56,197 |
| % Growth | 3.7% | -6.4% | 3.3% | – |
| Gross Profit | $39,430 | $33,903 | $40,640 | $38,751 |
| % Margin | 70% | 62.4% | 70% | 69% |
| EBITDA | $14,910 | $17,172 | $24,174 | $23,933 |
| % Margin | 26.5% | 31.6% | 41.6% | 42.6% |
| Net Income | $4,278 | $4,863 | $11,836 | $11,542 |
| % Margin | 7.6% | 9% | 20.4% | 20.5% |
| EPS Diluted | 2.39 | 2.72 | 6.63 | 6.45 |
| % Growth | -12.1% | -59% | 2.8% | – |
| Operating Cash Flow | $18,806 | $22,839 | $24,943 | $22,777 |
| Capital Expenditures | -$974 | -$777 | -$695 | -$787 |
| Free Cash Flow | $17,832 | $22,062 | $24,248 | $21,990 |